Long-Term Results of RCT: Neoadjuvant chemoradiotherapy vs. upfront surgery for resectable and borderline resectable pancreatic cancer.
28 Jan, 2022 | 08:01h | UTCNeoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)